UCB Announces Positive Results From Two New Phase III Studies In Rheumatoid Arthritis

Tue, 02 Jan 2007 03:00 PM EST

... UCB today announced positive top-line results for signs and symptoms from two new phase III studies for CIMZIA(TM) (certolizumab pegol), the first Fab' fragment anti-TNF (Tumor Necrosis Factor), in the treatment of rheumatoid arthritis. [click link for full article] ...